A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer.

Trial Profile

A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2012

At a glance

  • Drugs Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Pegdinetanib
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 24 Mar 2012 This trial has been recruiting in France and discontinued in Italy.
    • 24 Mar 2012 Planned number of patients changed from 116 to 135 as reported by European Clinical Trials Database record.
    • 13 Jan 2012 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top